Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup>Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).

导出 OA

翻译打印收藏纠错

作者： Jeremie,Calais ^[1] ; Johannes,Czernin ^[1] ; Pan,Thin ^[1] ; Jeannine,Gartmann ^[1] ; Kathleen,Nguyen ^[1] ; Wesley R,Armstrong ^[1] ; Martin,Allen-Auerbach ^[1] ; Andrew,Quon ^[2] ; Shadfar,Bahri ^[3] ; Pawan,Gupta ^[4] ; Linda,Gardner ^[5] ; Magnus,Dahlbom ^[6] ; Beilei,He ^[5] ; Rouzbeh,Esfandiari ^[7] ; David,Ranganathan ; Ken,Herrmann ; Matthias,Eiber ; Wolfgang P,Fendler ; Ebrahim,Delpassand

作者单位： Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California. ^[1] Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland. ^[2] Excel Diagnostics and Nuclear Oncology Center, Houston, Texas. ^[3] RadioMedix, Inc., Houston, Texas. ^[4] Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; and. ^[5] Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany. ^[6] Excel Diagnostics and Nuclear Oncology Center, Houston, Texas.;RadioMedix, Inc., Houston, Texas. ^[7]

关键词 177Lu RESIST-PC metastatic castration-resistant prostate cancer molecular radiotherapy prospective randomized phase 2 trial prostate-specific membrane antigen radionuclide therapy safety theranostics